Top

Published in:

Open Access 01-12-2021 | Lung Cancer | Research

Genetic polymorphisms and haplotypes of ERCC1 and ERCC2 associated with quality of life, depression, and anxiety status among patients with lung cancer

Authors: Yunxiang Tang, Ruike Zhang, Yinan Li, Shuyu Xu, Hao Wang, Jingzhou Xu, Lei Xiao, Yajing Wang, Jing Du, Yujia Huang, Tong Su

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

Patients with lung cancer (LC) have a poor quality of life (QoL) and easily suffer from psychological diseases. Previous studies focused less on the relationship between genetic factors and QoL, depression, and anxiety status in LC patients. The current study is intended to explore the relationship between SNPs and haplotypes of ERCC1 and ERCC2 and the QoL, depression and anxiety status of patients with LC.

Methods

QoL, depression and anxiety status were assessed in 291 LC patients using the European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30), EORTC Quality of Life Questionnaire-Lung Cancer 13 (QLQ-LC13), SDS and SAS. Nine tag SNPs of ERCC1 and ERCC2 were detected using an improved multiplex ligation detection reaction (iMLDR) technique. Haplotype analysis was conducted using the software Haploview 4.2. The association between SNPs or haplotypes and QoL or depression or anxiety in LC patients was analyzed by regression analysis.

Results

ERCC1 rs11615 was associated with emotional functioning (P = 0.027), and ERCC1 rs3212986 was associated with anxiety scores (P = 0.018). ERCC1 rs762562-rs3212986 haplotype was associated with cognitive function (P = 0.029), somatic function (P = 0.014) and dysphagia (OR = 3.32, P = 0.044). Patients with ERCC1 rs3212986-rs11615 AG haplotype had worse cognitive function (adjusted Beta = − 5.42) and somatic function (adjusted Beta = − 6.55) and had severer symptoms of loss of appetite (adjusted OR = 1.67) and dysphagia (adjusted OR = 4.43) (All adjusted P < 0.05). ERCC2 rs13181-rs3916874-rs238416 haplotype was associated with emotional functioning (P = 0.035), pain at other sites (OR 1.88, P = 0.014), chest pain (OR 0.42, P = 0.02), dysphagia (OR 2.82, P = 0.048), and anxiety status (OR 0.23, P = 0.009).

Conclusion

After adjustment for environmental factors, SNPs and haplotypes of ERCC1 and ERCC2 were associated with different domains of QoL, depression and anxiety in LC patients.

Available only for authorised users

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.CrossRefPubMed

Guo H, Chang Z, Wu J, Li W. Air pollution and lung cancer incidence in China: who are faced with a greater effect? Environ Int. 2019;132:105077. https://doi.org/10.1016/j.envint.2019.105077.CrossRefPubMed

Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ Jr, Wu YL, et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389(10066):299–311. https://doi.org/10.1016/S0140-6736(16)30958-8.CrossRefPubMed

Yang P, Cheville AL, Wampfler JA, Garces YI, Jatoi A, Clark MM, et al. Quality of life and symptom burden among long-term lung Cancer survivors. J Thorac Oncol. 2012;7(1):64–70. https://doi.org/10.1097/JTO.0b013e3182397b3e.CrossRefPubMedPubMedCentral

Mierzynska J, Piccinin C, Pe M, Martinelli F, Gotay C, Coens C, et al. Prognostic value of patient-reported outcomes from international randomised clinical trials on cancer: a systematic review. Lancet Oncol. 2019;20(12):E685–98. https://doi.org/10.1016/S1470-2045(19)30656-4.CrossRefPubMed

Hampton T. Patients' genes may influence quality of life after cancer chemotherapy. JAMA. 2004;292(6):673–4. https://doi.org/10.1001/jama.292.6.673.CrossRefPubMed

Sloan J, Zhao X. Genetics and quality of life. Curr Probl Cancer. 2006;30(6):255–60. https://doi.org/10.1016/j.currproblcancer.2006.09.001.CrossRefPubMed

Sprangers MAG, Thong MSY, Bartels M, Barsevick A, Ordonana J, Shi QL, et al. Biological pathways, candidate genes, and molecular markers associated with quality-of-life domains: an update. Qual Life Res. 2014;23(7):1997–2013. https://doi.org/10.1007/s11136-014-0656-1.CrossRefPubMedPubMedCentral

Simon GR, Ismail-Khan R, Bepler G. Nuclear excision repair-based personalized therapy for non-small cell lung cancer: from hypothesis to reality. Int J Biochem Cell B. 2007;39(7–8):1318–28. https://doi.org/10.1016/j.biocel.2007.05.006.CrossRef

10.

Olaussen KA, Postel-Vinay S. Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape. Ann Oncol. 2016;27(11):2004–16. https://doi.org/10.1093/annonc/mdw321.CrossRefPubMed

11.

Tan LM, Qiu CF, Zhu T, Jin YX, Li X, Yin JY, et al. Genetic polymorphisms and platinum-based chemotherapy treatment outcomes in patients with non-small cell lung Cancer: a genetic epidemiology study based meta-analysis. Sci Rep-Uk. 2017;7(1):5593. https://doi.org/10.1038/s41598-017-05642-0.

12.

Vilmar A, Santoni-Rugiu E, Sørensen JB. ERCC1, toxicity and quality of life in advanced NSCLC patients randomized in a large multicentre phase III trial. Eur J Cancer. 2010;46(9):1554–62. https://doi.org/10.1016/j.ejca.2010.02.045.CrossRefPubMed

13.

Yin J, Vogel U, Ma Y, Qi R, Wang H. HapMap-based study of the DNA repair gene ERCC2 and lung cancer susceptibility in a Chinese population. Carcinogenesis. 2009;30(7):1181–5. https://doi.org/10.1093/carcin/bgp107.CrossRefPubMed

14.

Kim SH, Lee GW, Lee MJ, Cho YJ, Jeong YY, Kim HC, et al. Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy. Lung Cancer. 2012;77(3):578–84. https://doi.org/10.1016/j.lungcan.2012.04.016.CrossRefPubMed

15.

Su T, Sun H, Lu XF, He C, Xiao L, He JW, et al. Genetic polymorphisms and haplotypes of BRCA1 gene associated with quality of life and survival among patients with non-small-cell lung cancer. Qual Life Res. 2020;29(10):2631–40. https://doi.org/10.1007/s11136-020-02509-2.CrossRefPubMed

16.

Thomas G, Sinville R, Sutton S, Farquar H, Hammer RP, Soper SA, et al. Capillary and microelectrophoretic separations of ligase detection reaction products produced from low-abundant point mutations in genomic DNA. Electrophoresis. 2010;25(10–11):1668–77.

17.

Zung WW. A rating instrument for anxiety disorders. Psychosomatics. 1971;12(6):371–9. https://doi.org/10.1016/S0033-3182(71)71479-0.CrossRefPubMed

18.

Zung WW. A self-rating depression scale. Arch Gen Psychiatry. 1965;12(1):63–70. https://doi.org/10.1001/archpsyc.1965.01720310065008.CrossRefPubMed

19.

Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Haes JC. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–76. https://doi.org/10.1093/jnci/85.5.365.CrossRefPubMed

20.

Bergman B, Aaronson NK, Ahmedzai S, Kaasa S. The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur J Cancer 1994;30A(5):635–42. https://doi.org/10.1016/0959-8049(94)90535-5.

21.

Peter F, Simon W, Desmond C. EORTC QLQ-C30 Reference Values; 2008.

22.

Barrett JC, Fry BA, Maller JB, Daly MJ. HAPLOVIEW: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21(2):263–5. https://doi.org/10.1093/bioinformatics/bth457.CrossRefPubMed

23.

Ettinger DS, Akerley W, Borghaei H, Chang AC, Hughes M. Non-small cell lung Cancer, version 6.2015. J Natl Compr Cancer Netw. 2013;11(6):645–53. https://doi.org/10.6004/jnccn.2013.0084.CrossRef

24.

Hamilton G, Rath B. Pharmacogenetics of platinum-based chemotherapy in non-small cell lung cancer: predictive validity of polymorphisms of ERCC1. Expert Opin Drug Metab Toxicol. 2018;14(1):17–24. https://doi.org/10.1080/17425255.2018.1416095.CrossRefPubMed

25.

Zulfan Z, Susanne V, Elise S, Geoffrey L, Bruce C. Genetic variations and cisplatin nephrotoxicity: a systematic review. Front Pharmacol. 2018;9:1111. https://doi.org/10.3389/fphar.2018.01111.

26.

Grenda A, Bach J, Krawczyk P, Nico M, Milanowski J. P2.01–44 promoter polymorphisms of TOP2A and ERCC1 genes as predictive factors for chemotherapy in non-small cell lung cancer patients. J Thorac Oncol. 2019;14(10):S656.CrossRef

27.

Anoushirvani AA, Aghabozorgi R, Ahmadi A, Arjomandzadegan M, Khalili S, Sahraei M, et al. The relationship between rs3212986C>a polymorphism and tumor stage in lung cancer patients. Cureus. 2019;11(4):e4423. https://doi.org/10.7759/cureus.4423.

28.

Dong Y, Xiao-Hui L, Wei D, Xin-Jian X, Xi-Yan W. Contribution of DNA repair xeroderma pigmentosum group D genotypes to pancreatic cancer risk in the Chinese Han population. Genet Mol Biol. 2017;41(1):18–26.CrossRef

29.

Chen S, Villeneuve L, Jonker D, Couture F, Guillemette C. ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients. Pharmacogenet Genomics. 2015;25(12):573–83. https://doi.org/10.1097/FPC.0000000000000168.CrossRefPubMed

30.

Yan X, Chen X, Li M, Zhang P. Prevalence and risk factors of anxiety and depression in Chinese patients with lung cancer:a cross-sectional study. Cancer Manag Res. 2019;11:4347–56. https://doi.org/10.2147/CMAR.S202119.CrossRefPubMedPubMedCentral

31.

Yang GS, Kumar S, Dorsey SG, Starkweather AR, Kelly DL, Lyon DE. Systematic review of genetic polymorphisms associated with psychoneurological symptoms in breast cancer survivors. 2019;27(2):351–71. https://doi.org/10.1007/s00520-018-4508-3.

32.

Young EE, Kelly DL, Shim I, Baumbauer KM, Lyon DE. Variations in COMT and NTRK2 influence symptom burden in women undergoing breast Cancer treatment. Biol Res Nurs. 2017;19(3):318–28. https://doi.org/10.1177/1099800417692877.CrossRefPubMedPubMedCentral

33.

Min J. Koh, Hei-Cheul, Jeung, Kee, Namkoong, Hyun, Cheol, Chung: influence of the \{BDNF\} Val66Met polymorphism on coping response to stress in patients with advanced gastric cancer. J Psychosom Res. 2014;77(1):76–80. https://doi.org/10.1016/j.jpsychores.2014.04.008.

34.

Schillani G, Martinis E, Capozzo MA, Era D, Giraldi T. Psychological response to cancer: role of 5-HTTLPR genetic polymorphism of serotonin transporter. Anticancer Res. 2010;30(9):3823–6.PubMed

35.

Schillani G, Era D, Cristante T, Mustacchi G, Richiardi M, Grassi L, et al. 5-HTTLPR polymorphism and anxious preoccupation in early breast cancer patients. Radiol Oncol. 2012;46(4):321–7. https://doi.org/10.2478/v10019-012-0024-0.CrossRefPubMedPubMedCentral

Title: Genetic polymorphisms and haplotypes of ERCC1 and ERCC2 associated with quality of life, depression, and anxiety status among patients with lung cancer
Authors: Yunxiang Tang
Ruike Zhang
Yinan Li
Shuyu Xu
Hao Wang
Jingzhou Xu
Lei Xiao
Yajing Wang
Jing Du
Yujia Huang
Tong Su
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Lung Cancer
Mood Disorders
Lung Cancer
Affective Disorder
Dysphagia
Lung Cancer
Anxiety
Dysphagia
Dysphagia
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08570-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

Randomized and dose-escalation trials of recombinant human serum albumin /granulocyte colony-stimulating factor in patients with breast cancer receiving anthracycline-containing chemotherapy

Types of second primary cancer influence overall survival in cutaneous melanoma

A novel treatment strategy for lapatinib resistance in a subset of HER2-amplified gastric cancer

Evaluation of functional outcome of bilateral kidney tumors after sequential surgery

Factors for the optimal selection of granulocyte colony-stimulating factor preparations and predictors for R-CHOP dose reductions/delays among patients with non-Hodgkin B-cell lymphoma (STOP FN in NHL 2 subanalysis)

Development and validation of nomograms to intraoperatively predict metastatic patterns in regional lymph nodes in patients diagnosed with esophageal cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer